Tessier Maude 4

4 · Ikena Oncology, Inc. · Filed Jan 20, 2022

Form 4

Period: 2022-01-18

Chief Business Officer

Transactions

Exercise/Conversion
Common Stock
2022-01-18$4.51/sh+8,265$37,275→ 100,578 total
Exercise/Conversion
Common Stock
2022-01-18$4.15/sh+24,606$102,115→ 92,313 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-18−38,915→ 5,560 total
Exercise: $2.94Exp: 2028-08-08→ Common Stock (38,915 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-18−8,265→ 28,963 total
Exercise: $4.51Exp: 2029-12-05→ Common Stock (8,265 underlying)
Exercise/Conversion
Common Stock
2022-01-18$2.94/sh+38,915$114,410→ 67,707 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-18−24,606→ 11,186 total
Exercise: $4.15Exp: 2029-03-19→ Common Stock (24,606 underlying)

Footnotes (3)

[F1]25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
[F2]25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
[F3]25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Documents

1 file